Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28779681 | 1.00 | HTT (0.47) | HTTTHRBATML3MBTL1ALDH1A1 | |
| SCHEMBL5120727 | 0.98 | HTT (0.44) | HTTTHRBATML3MBTL1ALDH1A1 | |
| SCHEMBL5116850 | 0.98 | HTT (0.44) | HTTTHRBATML3MBTL1ALDH1A1 | |
| SCHEMBL28513626 | 0.94 | CA1 (0.41) | HTTTHRBATML3MBTL1ALDH1A1 | |
| SCHEMBL28944441 | 0.94 | CA1 (0.41) | HTTTHRBATML3MBTL1ALDH1A1 | |
| SCHEMBL28944439 | 0.94 | CA1 (0.41) | HTTTHRBATML3MBTL1ALDH1A1 | |
| SCHEMBL27003453 | 0.94 | CA1 (0.41) | HTTTHRBATML3MBTL1ALDH1A1 | |
| SCHEMBL3487568 | 0.94 | CA1 (0.41) | HTTTHRBATML3MBTL1ALDH1A1 | |
| SCHEMBL28779723 | 0.93 | HTT (0.47) | HTTTHRBATML3MBTL1ALDH1A1 | |
| SCHEMBL5202228 | 0.93 | THRB (0.54) | HTTTHRBATML3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114717211-A | Imine reductase mutant M5 and application thereof in synthesis of azacyclo chiral amine | 江苏集萃分子工程研究院有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | HTT 2910/4885THRB 552/4885ATM 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.